London, United Kingdom
Ori Biotech, founded in 2015, is a notable player in the Cell and Gene Therapies (CGT) manufacturing arena, leveraging its bases in London and Philadelphia. The company has crafted a proprietary, automated, and flexible platform that simplifies the complex manufacturing processes needed for CGT, thereby providing patients with access to a new era of personalized medical treatments.
The platform is designed to relocate manufacturing hurdles to history by streamlining the scale-up process from pre-clinical stages to commercial levels. This aligns with their mission to enhance patient reach and facilitate lifesaving therapies.
Operating within industries like Automation, Biotechnology, and Health and Wellness, Ori Biotech continues to attract investor confidence. Their recent financial milestone was marked by a $100.00M Series B investment in January 2022, with backing from prominent investors such as Octopus Ventures, Amadeus Capital Partners, and Chimera Investments, indicating solid support for their visionary and technological advancements in the United Kingdom market.
